Android app on Google Play

Wedbush Starts Durata Therapeutics (DRTX) at Outperform; Safety, Potency, Convenience Underpin Positive Outlook of Dalbavancin

September 10, 2012 2:02 PM EDT Send to a Friend
Get Alerts DRTX Hot Sheet
Price: $12.78 +0.47%

Rating Summary:
    8 Buy, 2 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 34 | Down: 12 | New: 36
Trade DRTX Now!
Join SI Premium – FREE
Wedbush initiates coverage on Durata Therapeutics (NASDAQ: DRTX) with an Outperform. PT $20.00.

Analyst, Gregory R. Wade, said, "Durata’s potent IV once-weekly gram-positive dalbavancin will, we believe, garner meaningful market share in patients with serious skin and skin structure infections (abSSSI) and osteomyelitis, a serious and growing, difficult-to-treat infection that requires multiple weeks of antibiotic therapy...We believe Dalbavancin is significantly risk-reduced having already successfully achieved non-inferiority in 3 Phase III clinical trials and completed a substantive review of an NDA at FDA...We believe dalbavancin, with similar potency to CUBICIN (Nasdaq: CBST), augmented by a convenient once-weekly administration schedule will further grow this segment of the marketplace."

For an analyst ratings summary and ratings history on Durata Therapeutics click here. For more ratings news on Durata Therapeutics click here.

Shares of Durata Therapeutics closed at $9.86 yesterday.




You May Also Be Interested In


Related Categories

FDA, New Coverage

Add Your Comment